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Abstract 
Background: Increased expression of voltage-gated sodium channels (VGSCs) have been implicated with strong 
metastatic potential of human breast cancer in vitro and in vivo where the main culprits are cardiac isoform Nav1.5 
and its ‘neonatal’ splice variant, nNav1.5. Several factors have been associated with Nav1.5 and nNav1.5 gain of expres-
sion in breast cancer mainly hormones, and growth factors.
Aim: This study aimed to investigate the role of epigenetics via transcription repressor, repressor element silencing 
transcription factor (REST) and histone deacetylases (HDACs) in enhancing Nav1.5 and nNav1.5 expression in human 
breast cancer by assessing the effect of HDAC inhibitor, trichostatin A (TSA).
Methods: The less aggressive human breast cancer cell line, MCF-7 cells which lack Nav1.5 and nNav1.5 expression 
was treated with TSA at a concentration range 10–10,000 ng/ml for 24 h whilst the aggressive MDA-MB-231 cells was 
used as control. The effect of TSA on Nav1.5, nNav1.5, REST, HDAC1, HDAC2, HDAC3, MMP2 and N-cadherin gene 
expression level was analysed by real-time PCR. Cell growth (MTT assay) and metastatic behaviors (lateral motility and 
migration assays) were also measured.
Results: mRNA expression level of Nav1.5 and nNav1.5 were initially very low in MCF-7 compared to MDA-MB-231 
cells. Inversely, mRNA expression level of REST, HDAC1, HDAC2, and HDAC3 were all greater in MCF-7 compared to 
MDA-MB-231 cells. Treatment with TSA significantly increased the mRNA expression level of Nav1.5 and nNav1.5 in 
MCF-7 cells. On the contrary, TSA significantly reduced the mRNA expression level of REST and HDAC2 in this cell line. 
Remarkably, despite cell growth inhibition by TSA, motility and migration of MCF-7 cells were enhanced after TSA 
treatment, confirmed with the up-regulation of metastatic markers, MMP2 and N-cadherin.
Conclusions: This study identified epigenetics as another factor that regulate the expression level of Nav1.5 and 
nNav1.5 in breast cancer where REST and HDAC2 play important role as epigenetic regulators that when lacking 
enhances the expression of Nav1.5 and nNav1.5 thus promotes motility and migration of breast cancer. Elucidation of 
the regulatory mechanisms for gain of Nav1.5 and nNav1.5 expression may be helpful for seeking effective strategies 
for the management of metastatic diseases.
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Background
The ‘classic’ role of voltage-gated sodium channels 
(VGSC) is to mediate cell regenerative membrane depo-
larization and conduction of electrical signaling (action 
potentials) in traditionally ‘excitable’ cells such as nerve, 
skeletal, and heart muscle cells [1]. Recent evidences 
show that VGSCs are also functionally expressed in many 
types of carcinomas (cancers of epithelial origin), includ-
ing those of prostate [2, 3], breast [4, 5], lung (small-cell, 
non-small-cell and mesothelioma) [6–8], cervix [9], ovary 
[10], and colon [11].
In breast cancer, increased VGSC expression and activ-
ity, predominantly the cardiac isoform Nav1.5 and its 
‘neonatal’ splice variant, nNav1.5, correlates positively 
with metastatic potential in vitro [5]. In vivo, the mRNA 
expression of Nav1.5 and nNav1.5 was detected in biopsy 
samples of breast cancer with occurrence of lymph node 
metastasis [5] and in breast tumors [12]. Ex  vivo, using 
whole-cell patch clamp, cells in breast tumor tissue slices 
displayed fast inward  Na+ currents similar to currents 
detected in the aggressive human breast cancer cell line, 
MDA-MB-231 [13].
Apparently, a full elucidation of the regulatory mecha-
nisms for such gain of expression of Nav1.5 and nNav1.5 
may be helpful for seeking effective strategies for the man-
agement of metastatic diseases. At present, various stud-
ies have demonstrated that growth factors (epidermal 
growth factor, nerve growth factor) [14, 15], hormones 
[16],  Na+ concentration [17], and VGSC auxiliary 
β-subunits [18] can all regulate the expression of VGSC 
in cancer cells thus potentiating aggressiveness. Recently, 
epigenetic changes has been suggested to contribute to 
the overexpression of VGSC in aggressive cancer cells [19, 
20], though the notion remains to be tested. Herein, the 
role of epigenetics via transcription repressor, repressor 
element silencing transcription factor (REST) and histone 
deacetylases (HDACs) in enhancing Nav1.5 and nNav1.5 
expression in human breast cancer cells was assessed.
In classic non-excitable cells i.e. epithelial cell, the 
expression of a number of genes commonly expressed in 
neurons including VGSC e.g. Nav1.2 is repressed by the 
master of transcription repressor, REST [21–23]. REST is 
a zinc finger protein that binds to a conserved repressor 
element-1 in a large number of genes encoding funda-
mental neuronal traits [23] such as ion channels, synaptic 
vesicle proteins, and neurotransmitter receptors. REST 
mediates active repression via recruitment of HDACs 
[24, 25]. With the emergence of neuronal-like adapta-
tion of cancer to gain aggressiveness [26], REST has now 
proven to play important tumor-suppressor function 
[27].
HDAC is a chromatin modifying enzyme involved 
in the removal of an acetyl group on lysine residues of 
histone protein contributing to transcriptional silencing 
of genes [28]. So far, eighteen HDAC isoforms, grouped 
into four classes have been described in humans [29]. 
Owing to the discovery of epigenetic drugs such as 
HDAC inhibitors, cellular functions of HDAC on gene 
expression is progressively deciphered. Of particular, 
these drugs have led to better understanding for the role 
of HDAC in cancers. The best characterised and probably 
biologically most relevant HDAC in human cancers are 
class I isoforms HDAC1, HDAC2, and HDAC3 [30]. The 
expression patterns of HDAC1, HDAC2, and HDAC3 
have been evaluated in different types of cancers, includ-
ing gastric cancer [31], liver cancer [32], prostate cancer 
[33], breast cancer [34], renal cell cancer [35], ovarian 
[36] and endometrial carcinomas [37].
This study focused on examining the role of REST, 
HDAC1, HDAC2, and HDAC3 on influencing the 
expression of Nav1.5 and nNav1.5 in breast cancer that 
promote aggressiveness. In doing so, the expression 
level of Nav1.5, nNav1.5, REST, HDAC1, HDAC2, and 
HDAC3 were measured and compared between the less 
aggressive human breast cancer cells, MCF-7 and the 
aggressive, MDA-MB-231 cells. The effect of HDAC 
inhibitor, trichostatin A (TSA), on Nav1.5, nNav1.5, 
HDAC1, HDAC2, HDAC3, REST, MMP2 and N-cad-
herin gene expression and on cell motility and migration 
of the less metastatic human breast cancer cells, MCF-7, 
were investigated.
Methods
Cell culture
MCF-7 and MDA-MB-231 cell line were purchased from 
the American Type Culture Collection (ATCC) and were 
cultured in 10 cm or 35 mm plastic culture dishes (Bec-
ton–Dickinson, USA). Both of the cells were maintained 
in Dulbecco’s minimum essential medium (DMEM) 
(Nacalai Tesque, Japan) supplemented with 4 mM l-glu-
tamine (Gibco, USA), 5% of fetal bovine serum (FBS) 
(Gibco, USA) and 1% penicillin–streptomycin (Gibco, 
USA). Cultured cells were kept in a humidified incubator 
at 37  °C, 100% relative humidity and with 5% regulated 
 CO2.
Chemicals
TSA was purchased from Invivogen, USA and stock solu-
tions were prepared in 100% ethanol (Nacalai Tesque, 
Japan), sterile filtered and stored at −20 °C until use.
Cell viability and proliferation assays
Briefly, 3 × 104 cells/well were cultured in a 96-well cul-
ture plate and incubated at 37 °C for 24 h. The cells were 
treated with different concentrations of TSA for 24, 48 
and 72 h in triplicates. Medium was removed and 100 μl 
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of DMEM and 10  μl of 12  mM 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Invitro-
gen, USA) were added to each well and incubated for 4 h. 
85 μl of MTT solution was removed followed by addition 
of 50  μl dimethyl sulfoxide (DMSO) (Fisher Scientific, 
USA). The plate was incubated at 37  °C for 10 min and 
the absorbance was measured at 540  nm using Spec-
traMax M5 microplate reader (Molecular Device, USA).
Cell treatment regimes
5 ×  105 cells were cultured in 35  mm culture dish and 
were incubated at 37  °C for 24  h. Media was removed 
and TSA was added to the cells following the treatment 
concentration. The cells were incubated for 24 h and pre-
ceded for RNA extraction.
Quantitative real‑time reverse transcription polymerase 
chain reaction (qRT‑PCR) analysis
Total RNA was extracted using Sepasol method according 
to the protocol provided by the manufacturer (Nacalai, 
Tesque, Japan). Total RNA (1 µg) was converted to cDNA 
using the QuantiTect Reverse Transcription Kit (Qiagen, 
Germany) according to the manufacturer’s protocol. Real-
time PCR was performed using SensiFAST SYBR Hi-ROX 
kit (Bioline, UK) according to manufacturer’s protocol, 
in triplicates. Sequence primers used were as follows: 
β-actin forward, ATTGCCGACAGGATGCAGAAG-3′ 
and reverse, 5′-AGAAGCATTTGCGGTGGACG-3′. 
Nav1.5 forward, 5′-TTGCTTGTTATGGTCATTGGC-3′ 
and reverse, 5′-GTTGTTCATCTCTCTGTCCTCAT-3′, 
nNav1.5 forward, 5′-CTGCACGCGTTCACTTTCCT-3′ 
and reverse, 5′-GACAAATTGCCTAGTTTTATATTT-3′, 
HDAC1 forward, 5′-GGAAATCTATCGCCCTCACA-3′ 
and reverse, 5′-TTGCCACAGAACCACCAGTA-3′, 
HDAC2 forward, 5′-CCGTCTACCATGATGATCCTG-3′ 
and reverse 5′-GTCTTCACTGTTCCATCTCCTC-3′, 
HDAC3 forward, 5′-CGCTTCCACTCCGAGGACTA-3′ 
and reverse, 5′-CTGGGCAGTCATCGCCTAC-3′, REST 
forward, 5′-ACTAGACATATGCGTACTCATTCAG-3′ 
and reverse 5′-CCATTGTGAACCTGTCTTGC-3′, 
MMP2 forward, 5′-TCACTCCTGAGATCTGCAAAC 
AG-3′ and reverse 5′-TCACAGTCCGCCAAATGAAC-3′, 
and N-cadherin forward, 5′-GTCAACATCACTCTCA 
CCGA-3′ and reverse 5′-ATCCACAGCTCTTATTCT 
TCCA-3′. Quantitative real-time was performed in an 
ABI Prism 7000 Sequence Detection System (Life Tech-
nologies, USA) and the amplification conditions were as 
follows: initial activation for 10 min at 95 °C for one cycle, 
10 s at 95 °C and 30 s at 60 °C for 34 cycles. Ct values of 
target genes were normalised to β-actin and the relative 
mRNA expression of target genes were calculated by the 
 2−ΔΔCt method [38].
Wound healing assay
Lateral motility of cells was assessed using a monolayer 
wound healing assay. Cells were plated in 35 mm plastic 
culture dish at an initial density of 5 × 105 cells/dish and 
allowed to settle for 24 h prior to wound creation and any 
pharmacological treatment  (T0). Wounds were created 
by scratching the monolayer c ells using a p200 pipette 
tip at 90° angle. Wound widths were measured again 
after 24 h  (T24). Lateral motility was calculated according 
to the motility index formula  1 −  (T24/T0) [39] and the 
percentage of lateral motility was normalised to control 
(untreated).
Migration assay
Migration assay was performed using transwell cham-
bers with 8  μm pore inserts (Corning, USA). Briefly, 
5 × 104 cells in 300 μl of 1% serum medium were plated 
into the upper chambers and 750  μl medium with 10% 
serum was added as chemo attractant in lower chambers. 
After 24  h incubation, non-migrating cells were gently 
removed using cotton swab and the migrated cells (at 
the outer surface of membrane insert) were fixed with 
ice-cold methanol for 15  min. The cells were stained 
in 0.05% crystal violet for 15  min. Migrated cells were 
viewed under inverted microscope (10× magnification) 
and images were captured using a monochrome ProgRes 
 CFcool CCD camera (Jenoptik, Germany). Migrated cells 
in each insert were counted and averaged from 30 ran-
dom fields.
Statistical analysis
All data are expressed as the mean ±  SEM. Student’s t 
test was carried out to evaluate differences between two 
groups (treated vs untreated). Differences were consid-
ered to be significant for values of p < 0.05.
Results
MCF‑7 cells expressed low level of Nav1.5 and nNav1.5 
but higher REST expression
We compared the gene expression level of Nav1.5, 
nNav1.5 and REST by qRT-PCR in two human breast 
cancer cell lines, MDA-MB-231 (the highly aggressive 
human breast cancer cells) and MCF-7 (the less aggres-
sive human breast cancer cells). The expression level 
of Nav1.5 and nNav1.5 was very low in MCF-7 cells 
compared to MDA-MB-231 cells. MDA-MB-231 cells 
expressed 187 ± 31.5-fold (p < 0.01) and 61 ± 20.4-fold 
(p < 0.05) greater Nav1.5 and nNav1.5 mRNA expression, 
respectively, compared to MCF-7 cells (Fig.  1a, b). The 
expression level of REST was significantly lower in MDA-
MB-231 cells (0.4 ± 0.03-fold, p < 0.00001) compared to 
MCF-7 cells.
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MDA‑MB‑231 cells expressed low level of HDAC1, HDAC2, 
and HDAC3
We measured the basal expression levels of HDAC1, 
HDAC2 and HDAC3 in MDA-MB-231 cells compared 
to MCF-7 cells (without TSA treatment). As presented 
in Fig. 2, HDAC1, HDAC2 and HDAC3 exhibited lower 
mRNA expression in MDA-MB-231 compared to MCF-7 
cells. However, only HDAC2 showed a significantly lower 
expression in MDA-MB-231 cells (p < 0.05).
TSA increased the mRNA expression level of Nav1.5 
and nNav1.5 in MCF‑7 cells
Next, we examined the effect of TSA treatment on Nav1.5 
and nNav1.5 mRNA expression by qRT-PCR. In compari-
son to untreated cells, our results showed that treatment 
with 1000 and 10,000  ng/ml TSA for 24  h significantly 
increased the expression of Nav1.5 by 26  ±  7.0-fold 
(p < 0.05) and 39 ± 5.1-fold (p < 0.01), respectively (Fig. 3a 
and b). Similarly, the expression of nNav1.5 was increased 
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Fig. 1 MCF-7 express low expression of Nav1.5 and nNav1.5 but higher REST expression compared to MDA-MB-231. Relative mRNA expression level 
of Nav1.5 and nNav1.5 was measured using qRT-PCR where β-actin was used as housekeeping gene. a The expression of Nav1.5 in MDA-MB-231 
normalised to MCF-7 cells. b The expression of nNav1.5 in MDA-MB-231 normalised to MCF-7 cells. c The expression of REST in MDA-MB-231 nor-
malised to MCF-7 cells. Data were collected from n = 3 independent experiments, presented as mean ± SEM. Unpaired Student’s t test *p < 0.05, 
**p < 0.01, and *****p < 0.00001
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Fig. 2 HDAC2 is significantly lower in MDA-MB-231 cells compared 
to MCF-7 cells. Relative mRNA expression level of HDAC1, HDAC2 
and HDAC3 was measured using qRT-PCR where β-actin was used 
as housekeeping gene. mRNA expression of each HDAC in MDA-
MB-231 was normalised to HDAC in MCF-7 cells. Data were collected 
from n = 3 independent experiments, presented as mean ± SEM. 
Unpaired Student’s t test *p < 0.05
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by 8 ± 2.9-fold and 11 ± 1.5-fold (p < 0.01) with 1000 and 
10,000 ng/ml TSA, respectively (Fig. 3c and d).
TSA reduced the mRNA expression level of REST in MCF‑7 
cells
In comparison to untreated cells, our results showed that 
gene expression of REST was significantly down-regu-
lated to 0.8 ±  0.1 (p  <  0.05), 0.3 ±  0.1 (p  <  0.001) and 
0.2 ± 0.03 (p < 0.0001) with increasing dose of 100, 1000 
and 10,000 ng/ml TSA, respectively (Fig. 4).
HDAC2 mRNA expression level was downregulated by TSA 
in MCF‑7 cells
Next, the effect of TSA on the mRNA expression of 
HDAC1, HDAC2 and HDAC3 in MCF-7 cells were 
analysed by qRT-PCR. The expression of HDAC1 was 
reduced but not significant, with concentrations of 
100–10,000  ng/ml TSA by 0.97  ±  0.1-fold, 0.8  ±  0.2-
fold and 0.83  ±  0.3-fold, respectively. HDAC2 expres-
sion was significantly down-regulated by ~0.6 ± 0.1-fold 
(p < 0.001) and ~0.5 ± 0.1-fold (p < 0.001) with concen-
trations of 1000 and 10,000  ng/ml TSA, respectively. In 
contrast, the expression of HDAC3 was significantly 
increased by 2 ± 0.4-fold (p < 0.05) with 1000 ng/ml TSA 
(Fig. 5).
TSA caused growth suppression in MCF‑7 cells
To determine the effect of TSA on cell growth, MCF-7 
cells were treated with 10–10,000  ng/ml of TSA for 
24, 48 and 72 h. As presented in Fig. 6, cell growth was 
reduced in dose- and time-dependent manner by TSA. 
Cell growth at 24, 48, and 72 h was reduced by 21 ± 16.0, 
52  ±  7 and 69  ±  4.7%, respectively, with 10,000  ng/ml 
TSA.
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Fig. 3 TSA increased the expression of Nav1.5 and nNav1.5 in MCF-7 cells. MCF-7 cells were treated with 10–10,000 ng/ml TSA for 24 h. Relative 
mRNA expression level was measured using qRT-PCR where β-actin was used as housekeeping gene. a Relative mRNA expression level of Nav1.5 
normalised to untreated in MCF-7 cells after treatment. b Gel electrophoresis images of qRT-PCR products of Nav1.5. c Relative mRNA expression 
level of nNav1.5 normalised to untreated in MCF-7 after treatment. d Gel electrophoresis images of qRT-PCR products of Nav1.5. For gel images, lane 
1 untreated, lane 2 control ethanol (qRT-PCR data not shown), lanes 3–6 10, 100, 1000 and 10,000 ng/ml TSA, lane 7 non-template control. Data were 
collected from n = 3 independent experiments, presented as mean ± SEM. Unpaired Student’s t test *p < 0.05 and **p < 0.01
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TSA enhanced lateral motility and migration of MCF‑7 cells
To investigate the effect of TSA on cell metastatic behav-
iors of MCF-7 cells, we performed wound healing and 
migration assay. As shown in Fig.  7, cell motility was 
enhanced by ~20  ±  8.2% and ~90  ±  40.2% at concen-
tration of 100 and 1000  ng/ml TSA, respectively. How-
ever, at 10,000  ng/ml TSA, motility was only enhanced 
by 40  ±  23.0%, compared to the untreated cells due to 
toxicity effect. Similarly, our data revealed that TSA 
at 1000  ng/ml significantly enhanced the migration of 
MCF-7 cells by ~300 ± 117.5% (p < 0.05) (Fig. 8). Again, 
at 10,000  ng/ml TSA, migration was only enhanced by 
107 ± 41.1% (p < 0.05), compared to the untreated cells 
due to growth inhibition effect.
mRNA expression of MMP‑2 and N‑cadherin was 
upregulated by TSA
The mRNA expression of two metastasis markers, 
MMP2 and N-cadherin was investigated to confirm 
increased in metastatic behaviours in MCF-7 cells by 
TSA. We found that mRNA expression of MMP2 was 
significantly upregulated by ~16  ±  2.8-fold (p  <  0.01) 
and 22 ± 2.9-fold (p < 0.01) with concentrations of 1000 
and 10,000 ng/ml TSA, respectively (Fig. 9a and b). Simi-
larly, N-cadherin mRNA expression was also enhanced 
by 2.8 ± 0.6-fold (p < 0.05) and 5.3 ± 1.4-fold (p < 0.05) 
at the same concentrations of TSA where MMP2 mRNA 
expression increased (Fig. 9c and d).
Discussion
In search to understand factors that contribute to the 
enhancement of VGSC expression in aggressive can-
cers, reports have demonstrated that the primary regula-
tors are hormones [16], growth factors [14, 15], auxiliary 
β-subunits [18] and auto-regulation via  Na+ concentra-
tion [17, 38]. Though studies have shown that VGSCs are 
highly expressed in various tumour types with no altera-
tion of their genetic code [19, 20], epigenetic regulation 
of VGSCs in these cancers is not known.
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Fig. 5 TSA reduced the HDAC1 and HDAC2 expression. MCF-7 cells 
were treated with 10–10,000 ng/ml TSA for 24 h. Relative mRNA 
expression level of HDAC1, HDAC2 and HDAC3 was measured 
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normalised to untreated. Data were collected from n = 4 independ-
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Fig. 6 TSA caused dose- and time-dependent growth suppression 
in MCF-7 cells. MCF-7 cells were treated with TSA at concentration of 
10–10,000 ng/ml for 24–72 h and cell growth was measured using 
MTT assay. The cell growth of untreated control cells was considered 
as 100%. Data were collected from n = 3 independent experiments, 
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To our knowledge, this is the first investigation on 
the regulatory role of epigenetic regulators, REST and 
HDACs on the expression of Nav1.5 and nNav1.5 in 
breast cancer that promote aggressiveness.
Firstly, we showed that less aggressive human breast 
cancer cells, MCF-7 expressed significantly lower level 
of Nav1.5 (p < 0.01) and nNav1.5 (p < 0.05) mRNA 
expression than aggressive human breast cancer cells, 
MDA-MB-231. Inversely, basal mRNA expression level 
of REST, HDAC1, HDAC2 and HDAC3 was higher in 
MCF-7 compared to MDA-MB-231 cells. In excitable 
cells e.g. neurons, REST dependence of VGSC expression 
suppression has been reported and confirmed several 
time [22, 40–42]. However in cancers, increased expres-
sion of Nav1.5/nNav1.5 and lack of REST expression 
level have been separately reported to be associated 
with breast cancer aggressive phenotype [5, 39, 40, 43]. 
Meanwhile, in adult heart, inhibition of REST resulted in 
re-expression of various neonatal genes including those 
encoding ‘neonatal’ ion channels such as the hyperpo-
larization-activated, cyclic nucleotide-gated channels 
and T-type  Ca2+ channels [44]. From here we postulated 
REST-Nav1.5/nNav1.5 interrelation in breast cancer. 
With extensive reports demonstrating REST epigenetic 
regulation is dependent on its ability to recruit HDACs 
for transcriptional repression activity [45], therefore, 
higher mRNA expression level of HDAC1, HDAC2, and 
HDAC3 in MCF-7 were expected. Recent study showed 
that HDAC1 was highly expressed in hormone receptor 
positive breast tumor [34] which linked to MCF-7 cells, 
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Fig. 7 TSA enhanced motility of MCF-7 cells. Lateral motility was assed according to wound healing assay. a (upper panel) Representative scratch 
wound images of MCF-7 cells at 0 h and (lower panel) 24 h treated with TSA at 100–10,000 ng/ml. b The percentage of motility index was quanti-
fied according to the formula 1 − (T24/T0) and normalised to untreated. Data were collected from n = 3 independent experiments, presented as 
mean ± SEM
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a human breast cancer cell line widely used for in  vitro 
model with positive estrogen receptor. Our postulation 
extended to REST-HDAC-Nav1.5/nNav1.5 interrelation 
in breast cancer.
Studies have shown HDAC inhibitors are able to 
restore the expression of VGSC isoforms in certain 
pathological conditions arisen from abnormally repres-
sion of VGSCs. For example, TSA was demonstrated 
to re-express Nav1.8 protein expression in dorsal root 
ganglion of nerve injury-induced neuropathic pain [46]. 
Similarly, with another famously known HDAC inhibitor, 
suberoylanilide hydroxamic acid (SAHA), re-expression 
of Nav1.5 protein expression was achieved in Duchenne 
muscular dystrophic mice model which lack Nav1.5 [47]. 
Additionally, with another known HDAC inhibitor, val-
proic acids (VPA), chronic treatment with VPA up-reg-
ulates the mRNA and cell surface expression of Nav1.7 
in adrenal chromaffin cells [48]. Herein, TSA treatment 
resulted in a significant increase of Nav1.5 and nNav1.5 
mRNA expression level in MCF-7 cells (p < 0.01 at 10 000 
ng/ml TSA). Subsequently, the effect of TSA on HDACs 
and REST gene expression were measured to ensure that 
the observed changes in Nav1.5 and nNav1.5 expression 
stemmed from REST/HDACs targeting. Indeed, mRNA 
expression level of REST, HDAC1 and HDAC2 in MCF-7 
cells was downregulated by TSA (though only effect on 
REST and HDAC2 was statistically significant, p < 0.05).
In normal epithelial cells, REST is expressed abun-
dantly and functions as tumor suppressor [49] where lack 
of REST have been implicated in carcinomas of breast 
[50], colorectal [27], and small cell lung [51]. In fact, 
REST is shown to be lost in breast tissues of patients with 
aggressive phenotype (significant poor prognosis and 
more than twice as likely to undergo disease recurrence 
within the first 3 years after diagnosis) [52]. The sig-
nificantly lower REST expression detected in aggressive 
Nav1.5/nNav1.5-expressing MDA-MB-231 cells com-
pared to less aggressive MCF-7 and REST downregula-
tion followed by up-regulation of Nav1.5/nNav1.5 after 
TSA treatment in MCF-7 cells support our hypothesis of 
REST interrelation with Nav1.5/nNav1.5.
Meanwhile, reports demonstrated that HDAC1 and 
HDAC2 have a high degree of homology and are able 
to form a complex in the nucleus [45, 46] which explain 
*
*
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Fig. 8 TSA enhanced migration of MCF-7 cells. Migration was assessed according to transwell migration assay. Migrated cells were viewed under 
inverted microscope (×10 magnification) and images were captured using a monochrome ProgRes  CFcool CCD camera (Jenoptik, Germany). 
Migrated cells in each insert were counted and averaged from 30 random fields. a Representative images of migrated MCF-7 cells from one 
field view. b The percentage of migrated cells normalised to untreated. Data were collected from n = 3 independent experiments, presented as 
mean ± SEM. Unpaired Student’s t test *p < 0.05
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the similar effects obtained by TSA on both molecules 
in MCF-7 cells. In our model of less aggressive breast 
cancer, the significant reduction of HDAC2 expression 
was in accordance to colon cancer where HDAC2 was 
reported to share similar feature to those of tumor-sup-
pressor genes when mutation-loss of HDAC2 function 
lead to oncogenesis [53].
On the contrary, HDAC3 expression was significantly 
increased after TSA treatment (p < 0.05). The increased 
pattern of HDAC3 gene expression level by TSA in 
MCF-7 cells was similar to that reported by Duong et al. 
[54] using the similar cell line. Opposite to HDAC1/
HDAC2, overexpression of HDAC3 in breast cancer is 
associated with clinicopathological indicator of disease 
progression [34], which is in line with our result , HDAC3 
increased of expression after treatment with TSA in 
MCF-7. The role of HDAC3 as tumour suppressor gene 
is only recognisable in hepatocellular carcinomas, where 
previously, Bhaskara et  al. [55] observed that liver-spe-
cific HDAC3 knockdown resulted in overt hepatocellular 
carcinomas. Thus, our results support the role of HDAC2 
as another epigenetic regulator for Nav1.5 and nNav1.5 
expression in breast cancer.
TSA was first recognized for its anticancer activ-
ity via cell cycle arrest and apoptosis in several types of 
cancer including breast cancer [51, 52]. The drug has 
been reported to induce caspase activity and apopto-
sis in MCF-7 cells via a cytochrome c-dependent path-
way [56]. Unfortunately, in clinical experiments, HDAC 
inhibitors including TSA seem to have serious limita-
tions which hindered their therapeutic potential. For 
example, the current two structurally distinct HDAC 
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Fig. 9 MMP2 and N-cadherin mRNA expression in MCF-7 cells was upregulated by TSA. Relative mRNA expression level was measured using 
qRT-PCR where β-actin was used as housekeeping gene. a Relative mRNA expression level of MMP2 normalised to untreated. b Gel electrophoresis 
images of qRT-PCR products of MMP2. c Relative mRNA expression level of N-cadherin normalised to untreated. d Gel electrophoresis images of 
qRT-PCR products of N-cadherin. For gel images, lane 1 untreated, lanes 2–4 100, 1000 and 10,000 ng/ml TSA, lane 5 non-template control. Data 
were collected from n = 3 independent experiments, presented as mean ± SEM. Unpaired Student’s t test *p < 0.05 and **p < 0.01
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inhibitors – SAHA (vorinostat, Zolinza™) and FK228 
(romidepsin, Istodax™), both are reported to have not 
been effective in clinical trials involving solid tumors 
i.e. refractory breast, colorectal, non-small cell lung and 
thyroid cancers [57] and most importantly, these drugs 
cause serious cardiac toxicity [58].
In this study, despite of growth inhibition by TSA, 
remarkably, motility and migration (p < 0.05) of MCF-7 
cells were still significantly increased. These findings 
were in line with several other studies which demon-
strated similar enhancement of metastatic parameters 
e.g. invasion and migration by TSA in various human 
cancers in vitro including those of neuroblastoma, men-
ingioma, and prostate [59], rhabdomyosarcoma [60], 
breast, gastric, liver, and lung cancer cell lines [61]. In 
fact, in  vivo, treatment with TSA also significantly pro-
motes metastasis in nude mice [61]. Subsequently, the 
underlying mechanism of metastatic enhancement by 
TSA was reported to be due to up-regulation of meta-
static related markers e.g. urokinase plasminogen acti-
vator [59], PKCs [61] and Ezrin [60]. Additionally, TSA 
also led to prostate cancer aggressiveness via induction of 
epithelial-to-mesenchymal transition phenotype which 
associated with increased expression of transcription fac-
tors ZEB1, ZEB2 and Slug, and mesenchymal markers 
such as vimentin, N-cadherin and fibronectin [62]. As in 
the present study, enhancement of motility and migration 
of MCF-7 cells by TSA were likely due to the increased 
expression level of Nav1.5 and nNav1.5. Both Nav1.5 and 
nNav1.5 are already recognised as a potent metastatic 
gene in potentiating breast cancer metastatic parameters 
i.e. motility, migration and invasion when specific VGSC 
blocker, TTX and other VGSC blockers e.g. phenytoin, 
ranolazine have all precisely suppressed breast cancer 
metastasis in vitro and in vivo even at dose concentration 
that does not interfere with proliferation [5, 13, 63–66]. 
Enhanced motility and migration of MCF-7 cells after 
TSA treatment were also pivotal to support the func-
tional re-expression of Nav1.5/nNav1.5. Importantly, our 
findings could explicate cellular mechanisms for the pre-
vious disappointments in clinical experience with HDAC 
inhibitors in patients with solid tumors.
Conclusions
Overall, our study demonstrated that epigenetics play role 
in controlling Nav1.5/nNav1.5 expression breast cancer. 
Downregulation of REST and HDAC2 expression level 
by TSA lead to enhanced Nav1.5 and nNav1.5 expres-
sion that transformed the less aggressive, MCF-7 cells to 
gain aggressiveness. We postulated that when REST and 
HDAC2 are lacking in breast cancer, enhance expression 
of Nav1.5 and nNav1.5 promotes aggressiveness.
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